FGF21 and myocardial infarction: Administration of recombinant FGF21 (50 ng/gm for each dose, 2 doses per day with a 12 hr interval for a total period of 3 days) to FGF21−/− mice caused a significant drop in the fraction of myocardial infarcts compared to PBS administration (Fig. 5E and 5F).